EUCTR2011-000757-22-IT进行中（未招募）不适用
A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to alternative 2-dose schedules in 9 - 14 year old healthy females compared to the standard 3-dose schedule for GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in 15 - 25 year old healthy females - HPV-070 PRI
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,428
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. A female between, and including, 9 and 25 years of age at the time of the first vaccination;2.Written informed consent obtained from the subject/from the parent(s)/LAR(s) of the subject prior to enrolment in the study. In addition, subjects below the legal age of consent should sign and personally date a written informed assent form;3.Healthy subjects as established by medical history and clinical examination before entering into the study; 4.Female subjects of non-childbearing potential may be enrolled in the study;5.Nonchildbearing potential is defined as pre-menarche, current tubal ligation,hysterectomy, ovariectomy or post-menopause; 6.Female subjects of childbearing potential may be enrolled in the study, if the subject:a. has practiced adequate contraception for 30 days prior to vaccination,b. has a negative pregnancy test on the day of vaccination, c.has agreed to continue adequate contraception during the entire vaccination period and up to two months after the last study vaccine dose.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1095
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 333
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnant or breastfeeding;2.A female planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the entire vaccination period and up to two months after the last study vaccine dose;3.Previous vaccination against HPV or planned administration of another HPV vaccine during the study other than that foreseen in the protocol;4.Child in care;5.Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 36);6.Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine/product dose. For corticosteroids, this will mean prednisone = 20 mg/day (for adult subjects) or = 0.5 mg/kg/day (for paediatric subjects), or equivalent. Inhaled and topical steroids are allowed;7.History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccines;8.Cancer or autoimmune disease under treatment;9.Planned administration/administration of a vaccine/product not foreseen by the study protocol within 30 days before each dose of vaccine. Administration of routine meningococcal, hepatitis B, hepatitis A, inactivated influenza, diphtheria/tetanus and/or diphtheria/tetanus-containing vaccine up to 8 days before each dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window;10.Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device);11.Previous administration of MPL or AS04 adjuvant;12.Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period. 13.Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required);14.Family history of congenital or hereditary immunodeficiency. 15.Major congenital defects or serious chronic illness;16.Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, which in the opinion of the investigator precludes administration of the study vaccine;17.Acute disease and/or fever at the time of enrolment.Fever is defined as temperature = 37.5°C (99.5°F) on oral, axillary or tympanic setting, or = 38.0°C (100.4°F) on rectal setting;18. Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.Enrolment will be deferred until condition is resolved.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of immunogenicity and safety of two 2-dose Human Papillomavirus (HPV) vaccine schedules in 9-14 year old girls.EUCTR2011-000757-22-DEGlaxoSmithKline Biologicals1,428
进行中（未招募）
不适用
A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals? dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi-Pasteur-MSD?s DTPa-IPV (Tetravac), when co-administered with MMRV (Priorix Tetra) in 5 to 6-year-old healthy children. - dTpa-IPV-010Booster immunisation of healthy preschool children against diphtheria, tetanus, pertussis, poliomyelitis, mumps, measles and rubellaand first or second immunisation of healthy preschool children against varicella.MedDRA version: 9.1Level: LLTClassification code 10034738MedDRA version: 9.1Level: LLTClassification code 10013023MedDRA version: 9.1Level: LLTClassification code 10043376MedDRA version: 9.1Level: LLTClassification code 10036012EUCTR2008-006124-64-ITGlaxoSmithKline Biologicals
进行中（未招募）
不适用
An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal ofcoagulopathy induced by coumarin derivatives in subjects with acute major bleedingTherapy of major bleeding resulting from an acquired deficiency of vitamin K-dependent coagulation factors and proteins C and S due to use of oral anticoagulation therapyMedDRA version: 9.1Level: LLTClassification code 10009789Term: Coagulation factors decreasedMedDRA version: 9.1Level: LLTClassification code 10005103Term: BleedingEUCTR2007-007861-19-BGCSL Behring GmbH176
进行中（未招募）
不适用
A study to assess the efficacy of Beriplex P/N compared with plasma for quick reversal of anticoagulant medicines in patients who require an urgent surgeryPerioperative prophylaxis for emergency surgery in subjects who have an acquired deficiency of vitamin K-dependent coagulation factors and proteins C and SMedDRA version: 14.1Level: PTClassification code 10065667Term: Haemorrhage prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10009789Term: Coagulation factors decreasedSystem Organ Class: 100000004848EUCTR2007-007862-39-BGCSL Behring GmbH176
进行中（未招募）
不适用
An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin derivatives in subjects with acute major bleeding.This study looks into the therapy of major bleeding resulting from an acquired deficiency of vitamin K-dependant coagulation factors and proteins C and S due to use of oral anticoagulation therapy.MedDRA version: 9.1Level: LLTClassification code 10009789Term: Coagulation factors decreasedMedDRA version: 9.1Level: LLTClassification code 10005103Term: BleedingEUCTR2007-007861-19-PLCSL Behring GmbH176